Clinical Insights

Clinical Insights: March 6, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Letybo® (letibotulinumtoxinA-wlbg) Powder for Injection – New Drug Approval – February 29, 2024 – Hugel, a global total medical aesthetics company, announced that the company has received marketing approval…

Read More...

Clinical Insights: February 29, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Amtagvi™ (lifileucel) Suspension for Intravenous Infusion –New Orphan Drug Approval  –February 16, 2024 – The U.S. Food and Drug Administration approved Amtagvi™ (lifileucel), the first cellular therapy indicated for the…

Read More...

Clinical Insights: February 14, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Eohilia™ (budesonide) Oral Suspension – New Drug Approval – February 9, 2024 – Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia™ (budesonide oral suspension),…

Read More...

Clinical Insights: February 7, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Yescarta® (axicabtagene ciloleucel) Suspension for Intravenous Infusion – New Label Expansion – January 30, 2024 – Kite, a Gilead Company (Nasdaq: GILD), announced…

Read More...

Clinical Insights: January 24, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Balversa® (erdafitinib) Tablets – New Label Expansion – January 19, 2024 – The Food and Drug Administration approved erdafitinib (Balversa®, Janssen Biotech) for adult patients with locally advanced or metastatic…

Read More...

Clinical Insights: January 10, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Zelsuvmi™ (berdazimer sodium) Topical Gel – New Drug Approval – January 5, 2024 – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...

Clinical Insights: January 3, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Wainua™ (eplontersen) Injection – New Orphan Drug Approval – December 21, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...

Clinical Insights: December 20, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Welireg™ (belzutifan) – New Drug Approval – December 14, 2023 – The Food and Drug Administration approved belzutifan (Welireg™, Merck & Co., Inc.) for patients with advanced renal cell carcinoma…

Read More...

Clinical Insights: December 13, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Casgevy™ (exagamglogene autotemcel) – New Drug Approval – December 8, 2023 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced that the U.S. Food and Drug Administration…

Read More...

Clinical Insights: December 6, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage December 05, 2023 Fluorescein Sodium Injection (Resolved) December 01, 2023 Azacitidine Injection (Currently in Shortage) Hydroxypropyl Cellulose…

Read More...

Clinical Insights: November 29, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ogsiveo™ (nirogacestat) Tablets – New Drug Approval – November 27, 2023 – The U.S. Food and Drug Administration approved Ogsiveo™ (nirogacestat) tablets for adult patients with progressing desmoid tumors who…

Read More...

Clinical Insights: November 22, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Truqap™ (capivasertib) Tablets – New Drug Approval – November 16, 2023 – AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) has been approved in the US for the treatment of…

Read More...